Cwm LLC Has $1.37 Million Stock Position in Insulet Corporation $PODD

Cwm LLC raised its stake in Insulet Corporation (NASDAQ:PODD) by 8.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,370 shares of the medical instruments supplier’s stock after buying an additional 336 shares during the quarter. Cwm LLC’s holdings in Insulet were worth $1,373,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC increased its holdings in Insulet by 4.3% during the 1st quarter. GAMMA Investing LLC now owns 2,529 shares of the medical instruments supplier’s stock worth $664,000 after purchasing an additional 105 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Insulet by 13.9% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 3,028 shares of the medical instruments supplier’s stock worth $795,000 after buying an additional 370 shares during the period. Janney Montgomery Scott LLC boosted its position in shares of Insulet by 2.9% during the first quarter. Janney Montgomery Scott LLC now owns 5,405 shares of the medical instruments supplier’s stock worth $1,419,000 after buying an additional 154 shares during the period. QRG Capital Management Inc. grew its holdings in shares of Insulet by 75.6% during the first quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier’s stock worth $533,000 after buying an additional 874 shares in the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in shares of Insulet by 2.6% during the first quarter. State of Alaska Department of Revenue now owns 8,212 shares of the medical instruments supplier’s stock worth $2,156,000 after buying an additional 210 shares in the last quarter.

Insiders Place Their Bets

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Analyst Ratings Changes

PODD has been the topic of several research reports. Wells Fargo & Company boosted their target price on Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Leerink Partners boosted their price objective on shares of Insulet from $339.00 to $355.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 14th. The Goldman Sachs Group decreased their target price on shares of Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Finally, Citigroup reiterated a “buy” rating on shares of Insulet in a research note on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $348.05.

Insulet Stock Up 2.6%

Shares of PODD stock opened at $326.85 on Tuesday. Insulet Corporation has a 52-week low of $226.50 and a 52-week high of $353.50. The stock has a market cap of $23.01 billion, a price-to-earnings ratio of 99.35, a PEG ratio of 2.66 and a beta of 1.40. The firm’s 50-day moving average is $326.66 and its 200-day moving average is $303.10. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the previous year, the business earned $0.55 earnings per share. The business’s revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.